The Future of Clinical Trials: WHO’s Plan to Improve Access and Impact Worldwide 16 Oct 2024
Clinical trials have the potential to reshape healthcare and improve lives globally. However, to realise this fully, trials must be well-designed, ethically conducted, and efficiently managed. They need to answer key scientific questions that provide direct benefits to the people they aim to help.
Acknowledging the need for change, the World Health Organization (WHO) has introduced new guidelines to address the challenges that clinical trials face today.
At the core of this updated guidance is the goal of eliminating inefficiencies that slow down trials. This will help new treatment reach patients faster.
Complex approval processes and uncoordinated procedures in many countries—particularly in low- and middle-income regions—act as barriers, delaying access to life-saving innovations. These delays impact both public health and economic progress. WHO’s new guidelines aim to simplify these processes, allowing health interventions to be delivered more quickly and fairly across the globe.
This shift is about speeding up trials — and improving their quality. The guidelines stress the importance of engaging with patients and communities early in the process, ensuring that the research reflects real-world needs.
WHO also highlight the need to focus on underrepresented groups—such as children, pregnant women, and older adults—who are often excluded from clinical research yet stand to gain the most from these studies. By including these populations, WHO aims to generate results that are more relevant and impactful across a broader spectrum of people.
A key element of WHO’s recommendations is the use of risk-proportionate oversight. This approach tailors the level of monitoring and regulation to the specific risks associated with a trial, instead of applying the same level of scrutiny to all studies. By doing so, the system can reduce unnecessary bureaucracy while still safeguarding participant safety and safeguarding data integrity.
For the first time, WHO is providing practical guidance to national health authorities, regulatory bodies, and funders on how best to support clinical trials. The aim is to strengthen research and development (R&D) ecosystems worldwide, allowing countries to produce high-quality evidence on health interventions and improve access to innovative treatments.
These reforms are expected to make clinical trials more effective and equitable on a global scale.
Why Does This Matter?
Timely access to life-saving treatments relies on the inclusion of diverse patient groups. Yet, many such as children, pregnant women, and older adults remain underrepresented in clinical trials.
WHO’s guidance stresses the importance of involving these populations to ensure that healthcare advances benefit everyone. Their inclusion is both an ethical responsibility and a crucial step towards improving global health outcomes.
Additionally, WHO advocates for reducing the bureaucratic hurdles that often slow down clinical trials. The guidance aims to simplify procedures by tailoring oversight to the level of risk, while maintaining both participant safety and data reliability.
What Does the Future Look Like?
These new guidelines set the stage for faster, more inclusive clinical trials that better address real-world healthcare needs. For researchers, this means streamlined processes and more effective results. For patients, it promises quicker access to new treatments that are designed with their specific needs in mind.
Community engagement also plays a pivotal role in WHO’s vision.
The framework promotes the involvement of patients and the public throughout the trial process, fostering greater transparency and building trust. This collaborative approach ensures that research has a meaningful and lasting impact on people’s lives.
Key Actions Moving Forward
- Expand trial demographics
Ensure that underrepresented populations are included in trials. - Simplify procedures
Remove unnecessary steps to accelerate the trial process. - Promote data transparency
Share results openly to build public trust and enhance global knowledge.
These changes represent essential steps towards creating a more efficient and equitable future for healthcare.
For more details on WHO’s report, Guidance for Best Practices for Clinical Trials, click here.
If you are looking to advance development and innovation of your products, PMC has experts to help and support you. Please contact us for an initial chat via
hello@pharmamedic.co or call us on +44 (0) 207 691 4912.